BioPorto A/S (THOXF)
USD 0.29
(0.0%)
USD 0.29
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 29.65 Million DKK | -22.82% |
| 2022 | 38.41 Million DKK | 8.86% |
| 2021 | 35.29 Million DKK | -10.37% |
| 2020 | 39.37 Million DKK | 126.81% |
| 2019 | 17.36 Million DKK | 73.53% |
| 2018 | 10 Million DKK | 4.91% |
| 2017 | 9.53 Million DKK | 50.17% |
| 2016 | 6.35 Million DKK | 40.86% |
| 2015 | 4.5 Million DKK | -47.29% |
| 2014 | 8.55 Million DKK | -4.76% |
| 2013 | 8.98 Million DKK | -53.54% |
| 2012 | 19.32 Million DKK | 11.65% |
| 2011 | 17.31 Million DKK | -2.0% |
| 2010 | 17.66 Million DKK | 267.48% |
| 2009 | 4.8 Million DKK | 31.52% |
| 2008 | 3.65 Million DKK | -17.79% |
| 2007 | 4.44 Million DKK | -80.17% |
| 2006 | 22.41 Million DKK | 27.96% |
| 2005 | 17.52 Million DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 29.73 Million DKK | 0.29% |
| 2024 Q2 | 26.71 Million DKK | -10.16% |
| 2023 Q1 | 30.08 Million DKK | -21.7% |
| 2023 Q2 | 31.02 Million DKK | 3.14% |
| 2023 Q4 | 29.65 Million DKK | 9.27% |
| 2023 Q3 | 27.13 Million DKK | -12.55% |
| 2023 FY | 29.65 Million DKK | -22.82% |
| 2022 Q3 | 42.49 Million DKK | 9.06% |
| 2022 Q4 | 38.41 Million DKK | -9.58% |
| 2022 Q1 | 39.35 Million DKK | 11.5% |
| 2022 Q2 | 38.96 Million DKK | -0.99% |
| 2022 FY | 38.41 Million DKK | 8.86% |
| 2021 FY | 35.29 Million DKK | -10.37% |
| 2021 Q1 | 34.64 Million DKK | -12.02% |
| 2021 Q3 | 37.87 Million DKK | 14.74% |
| 2021 Q4 | 35.29 Million DKK | -6.81% |
| 2021 Q2 | 33 Million DKK | -4.72% |
| 2020 Q3 | 39.08 Million DKK | 18.43% |
| 2020 Q1 | 16.76 Million DKK | -3.4% |
| 2020 FY | 39.37 Million DKK | 126.81% |
| 2020 Q4 | 39.37 Million DKK | 0.73% |
| 2020 Q2 | 33 Million DKK | 96.82% |
| 2019 Q1 | 14.67 Million DKK | 46.64% |
| 2019 FY | 17.36 Million DKK | 73.53% |
| 2019 Q2 | 15.14 Million DKK | 3.24% |
| 2019 Q4 | 17.36 Million DKK | -11.44% |
| 2019 Q3 | 19.6 Million DKK | 29.42% |
| 2018 Q3 | 9.42 Million DKK | 12.8% |
| 2018 Q2 | 8.35 Million DKK | 3.85% |
| 2018 Q1 | 8.04 Million DKK | -15.59% |
| 2018 FY | 10 Million DKK | 4.91% |
| 2018 Q4 | 10 Million DKK | 6.1% |
| 2017 Q3 | 10.74 Million DKK | 34.1% |
| 2017 FY | 9.53 Million DKK | 50.17% |
| 2017 Q2 | 8.01 Million DKK | -15.57% |
| 2017 Q1 | 9.49 Million DKK | 49.5% |
| 2017 Q4 | 9.53 Million DKK | -11.28% |
| 2016 Q1 | 4.74 Million DKK | 5.21% |
| 2016 Q4 | 6.35 Million DKK | 20.63% |
| 2016 FY | 6.35 Million DKK | 40.86% |
| 2016 Q3 | 5.26 Million DKK | 5.92% |
| 2016 Q2 | 4.97 Million DKK | 4.79% |
| 2015 Q1 | 8.1 Million DKK | -5.25% |
| 2015 FY | 4.5 Million DKK | -47.29% |
| 2015 Q4 | 4.5 Million DKK | -49.06% |
| 2015 Q3 | 8.85 Million DKK | -4.53% |
| 2015 Q2 | 9.27 Million DKK | 14.39% |
| 2014 Q2 | 9.56 Million DKK | 15.79% |
| 2014 Q1 | 8.25 Million DKK | -8.05% |
| 2014 FY | 8.55 Million DKK | -4.76% |
| 2014 Q3 | 9.07 Million DKK | -5.04% |
| 2014 Q4 | 8.55 Million DKK | -5.79% |
| 2013 Q1 | 18.9 Million DKK | -2.17% |
| 2013 Q4 | 8.98 Million DKK | -7.17% |
| 2013 FY | 8.98 Million DKK | -53.54% |
| 2013 Q2 | 28.69 Million DKK | 51.76% |
| 2013 Q3 | 9.67 Million DKK | -66.29% |
| 2012 FY | 19.32 Million DKK | 11.65% |
| 2012 Q2 | 18.09 Million DKK | -4.87% |
| 2012 Q4 | 19.32 Million DKK | 11.9% |
| 2012 Q1 | 19.02 Million DKK | 9.87% |
| 2012 Q3 | 17.27 Million DKK | -4.54% |
| 2011 Q2 | 17.06 Million DKK | -6.84% |
| 2011 Q4 | 17.31 Million DKK | 2.53% |
| 2011 Q3 | 16.88 Million DKK | -1.07% |
| 2011 Q1 | 18.32 Million DKK | 3.71% |
| 2011 FY | 17.31 Million DKK | -2.0% |
| 2010 Q4 | 17.66 Million DKK | 5.49% |
| 2010 Q1 | 5.61 Million DKK | 16.85% |
| 2010 FY | 17.66 Million DKK | 267.48% |
| 2010 Q3 | 16.74 Million DKK | 220.11% |
| 2010 Q2 | 5.23 Million DKK | -6.87% |
| 2009 Q4 | 4.8 Million DKK | 0.0% |
| 2009 FY | 4.8 Million DKK | 31.52% |
| 2008 FY | 3.65 Million DKK | -17.79% |
| 2007 FY | 4.44 Million DKK | -80.17% |
| 2006 FY | 22.41 Million DKK | 27.96% |
| 2005 FY | 17.52 Million DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -721.813% |
| Arrayit Corporation | 7.49 Million USD | -295.526% |
| Atlantic International Corp. | 3.82 Million USD | -674.457% |
| Biocept, Inc. | 22.01 Million USD | -34.698% |
| Bioqual, Inc. | 18.93 Million USD | -56.569% |
| CardioGenics Holdings Inc | 1.79 Million USD | -1551.937% |
| DermTech, Inc. | 64.75 Million USD | 54.21% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 95.966% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -139.392% |
| iMD Companies, Inc. | 1.67 Million USD | -1671.038% |
| IDenta Corp. | 1.01 Million USD | -2826.592% |
| Interpace Biosciences, Inc. | 28.15 Million USD | -5.306% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -9851.77% |
| InVitro International | 78.99 Thousand USD | -37437.663% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | -50.291% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -22832.473% |
| Medical Imaging Corp. | 9.51 Million USD | -211.555% |
| NovelStem International Corp. | 4.2 Million USD | -604.956% |
| Optigenex Inc. | 9.57 Million USD | -209.813% |
| PharmChem, Inc. | 558.64 Thousand USD | -5207.645% |
| Proteome Sciences plc | 18.48 Million USD | -60.371% |
| Response Genetics, Inc | 15.86 Million USD | -86.872% |
| Rennova Health, Inc. | 49.66 Million USD | 40.301% |
| RushNet, Inc. | 6.23 Million USD | -375.253% |
| ScreenPro Security Inc. | 1.6 Million USD | -1752.508% |
| Stella Diagnostics Inc. | 18 Million USD | -64.678% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -261.422% |
| Todos Medical Ltd. | 50.15 Million USD | 40.884% |